• Press Releases.png

    Press Releases

OmniComm Systems, Inc. Acquires Promasys BV

November 12, 2013

CONTACT :

Dr Kuno van der Post
OmniComm Systems, Inc.
954-473-1254
kvanderpost@omnicomm.com

Download Press Release

Acquisition Propels OmniComm into the Far East Markets, Expands OmniComm’s Global Footprint, and Establishes 31 New Clients in Rapidly Growing Markets

Fort Lauderdale, FL, November 12, 2013 – OmniComm Systems, Inc. (OTC: OMCM), one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, today announced the acquisition of Promasys BV, a privately held Netherlands based company dedicated to the development and marketing of clinical trial software and related services designed specifically for academic research and investigator initiated trials.

Founded in 2004, Promasys BV boasts satisfied customers in the EU as well as China, Japan, Korea, and India – densely populated, significant emerging markets. The Promasys® software features localized foreign-language support making it easily deployed in most of the world including the Asia/Pacific region. The data capture technology is designed for ease of set-up and is ideally suited for investigator initiated clinical trials (IITs). Most EDC solutions are too complex to efficiently accommodate these academically focused trials. Traditionally, investigators have had to develop proprietary solutions or rely on a paper-based approach to manage their research data. The Promasys technology is the first commercially viable solution designed with the needs of the academic research environment in mind.

“The Promasys Suite is a logical fit within our portfolio of innovative EDC solutions,” stated Randy Smith, OmniComm’s Chief Technology Officer. “With the strong local language support and native iPad application support, the Promasys application is a great extension to OmniComm’s eClinical product line.”

In recent years there has been explosive growth in clinical trials in the Far East, particularly in China and India. A review of trial activity within clinicaltrials.gov in November 2011 showed that 12% of the world’s clinical studies were being carried out in Asia. By February 2013, this proportion had increased to 15%.i

“OmniComm is committed to supporting clinical research around the world and we are proud to have our EDC technology deployed in 56 countries currently,” stated Stephen Johnson, President and COO of OmniComm Systems. “The acquisition of Promasys BV offers a tremendous opportunity for further global expansion and strengthens our position as a leading provider of innovative EDC solutions worldwide. We are delighted to welcome Promasys BV and their clients to the OmniComm family.”

“Every day we make it our mission to provide clinical researchers and research organizations with the tools to efficiently conduct quality controlled clinical research,” commented Wolf Ondracek, General Manager of Promasys BV. “We are confident the OmniComm acquisition will further our vision and advance the introduction of our technology to a much larger audience of investigators and sponsors. Additionally, we will be able to offer enhanced value to Promasys clients by coupling our regional expertise with OmniComm’s intuitive EDC solutions that have been validated internationally.”

About OmniComm Systems

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.

About Promasys BV

Promasys develops innovative software for clinical data management and clinical trial workflow support. Promasys is unique in that it offers rich functionality for data management, an EDC, and an embedded quality system ensuring quality and integrity of the clinical data, without the need for the users to do any programming. Client focus is on academic research centers and hospitals, SME CRO's and SME pharmaceutical and biotech companies.

Promasys’ history goes back to 1988 when the development of the software was started by the Centre for Human Drug Research (www.chdr.nl), a leading early phase clinical research organization. Since then, Promasys software has been developed in continuous interaction first with CHDR’s clinical research professionals and later, after Promasys BV was established in 2004, also with researchers and clinical trial staff in academic hospitals in various parts of the world.Promasys BV has its office in CHDR’s new premises located in Leiden at 30 minutes from Amsterdam airport.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.